FDA has recently revised Form 356h: Application to Market a New or Abbreviated New Drug or Biologic for Human Use and Form 1571: Investigational New Drug Application (IND) to align with FDA User Fee requirements as well as make other improvements to data quality and ease of use.
These forms are required to be submitted with NDAs, ANDAs, BLAs and INDs. FDA uses this information in the review process and companies should be aware of these updates and are required to use the most current version of these forms.
Companies need to use the most recent update to Forms 356h and 1571 in their submissions.
View referenced article
Author(s)
Related Insights
April 22, 2026
Foley Viewpoints
Mexican Supreme Court Validates the Blocking of Bank Accounts
On April 6, 2026, the Mexican Supreme Court (“SCJN”), when ruling on the constitutional challenge (acción de inconstitucionalidad) 58/2022, recognized the constitutionality of Article 116 Bis 2 of the Credit Institutions Law (“LIC”), validating the blocking of bank accounts by the Mexican Ministry of the Treasury, through its Financial Intelligence Unit (“UIF”), based on the “Blocked Persons List” when there is sufficient evidence to believe that these persons are involved in crimes of (i) terrorist financing, (ii) operations with illicit funds, or (iii) related offenses. This precedent is of particular relevance for anyone who maintains bank accounts or performs transactions through the Mexican Financial System.
April 22, 2026
Foley Viewpoints
Patent analysis is increasingly shaping AI-driven target and drug candidate selection
Pun et al.'s recent review entitled “Target identification and assessment in the era of AI” in Nature Reviews Drug Discovery maps how…
April 20, 2026
Foley Viewpoints
Final Rule Exempts ICHRAs and Other Account-Based Plans from Medicare Part D-Creditable Coverage Notice
On April 6, 2026, the Department of Health and Human Services (HHS) published a final rule formally excluding account-based group health…